AstraZeneca and CRUK partner on drug trial
May 31, 2013Sales and Marketing AstraZeneca, CRUK
AstraZeneca is partnering with Cancer Research UK to develop a new oncology medicine that targets a number of different cancers. …
Avillion appoints chief business officer
May 31, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Avillion
Venture capitalist firm Avillion has announced the expansion of its leadership team with the appointment of Ramani Varanasi as chief …
Pfizer, UCB sell plants to smaller drugmakers
May 30, 2013Manufacturing and Production Pfizer, UCB
This week saw two pharma companies offload US manufacturing facilities to contract manufacturing organisations (CMOs), with Pfizer selling a plant …
Bad pharma, good pharma: an insider’s view
May 30, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bad pharma, Goldacre, NICE, transparancy
Most people in the pharmaceutical industry, particularly in the UK, will be well-acquainted with Ben Goldacre by now. He published his …
FDA approves GSK cancer drugs
May 30, 2013Sales and Marketing FDA, GSK
The FDA has approved two of GlaxoSmithKline’s cancer pills: BRAF-inhibitor Tafinlar and the first validated MEK-inhibitor, called Mekinist, both of …
NICE U-turn on Forxiga
May 30, 2013Sales and Marketing Forxiga, NICE
NICE has recommended Bristol-Myers Squibb and AstraZeneca’s diabetes drug Forxiga in final draft guidance after turning its back on the …
SCM Pharma appoints new director
May 30, 2013Manufacturing and Production, Research and Development, Sales and Marketing SCM Pharma
UK-based contract development and manufacturing organisation SCM Pharma has strengthened its senior management team by recruiting a director. Paul Bradley …
New HIV pill for UK
May 29, 2013Sales and Marketing Gilead, HIV, stribild
Gilead Sciences has launched Stribild, a once-daily single tablet regimen to combat HIV – the virus which causes AIDS – …
Amgen moves into Japanese market with Astellas deal
May 29, 2013Sales and Marketing Amgen, Astellas, Vectibix, Zhejiang
Amgen and Astellas have announced a new collaboration that will see them launch five new medicines in Japan from 2016, …
Diovan trials may have been run by Novartis staff
May 29, 2013Research and Development, Sales and Marketing Diovan, Novartis
Several post-marketing clinical trials of the blockbuster blood pressure drug Diovan may have been run by employees of the drug’s …
Valeant to buy B+L for $8.7 billion
May 29, 2013Sales and Marketing B+L, Valeant
Canadian firm Valeant Pharmaceuticals International is to buy Bausch + Lomb in an $8.7 billion deal which will see the …
Xarelto gets ACS indication
May 29, 2013Sales and Marketing ACS, Bayer, Xarelto
Bayer HealthCare’s bloodthinner Xarelto has expanded its reach in Europe with approval for secondary prevention after an acute coronary syndrome …
FDA rejects Valeant’s efinaconazole on packaging grounds
May 29, 2013Manufacturing and Production FDA, Valeant
Valeant Pharmaceuticals has had its application to market antifungal candidate efinaconazole turned down by the FDA because of issues related …
Pharmaniaga joins push into MENA with Saudi JV
May 29, 2013Manufacturing and Production MENA, Pharmaniaga, Saudi
Malaysian drugmaker Pharmaniaga has formed a joint venture in Saudi Arabia as it starts a push into the fast-growing Middle …
Grant NICE greater trial data access – report
May 29, 2013Research and Development, Sales and Marketing Goldacre, NICE, transparency, trials
A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …
Wireless pill bottle wins Boehringer challenge
May 29, 2013Medical Communications Boehringer, brett wells, wireless
Developers of a pill bottle that wirelessly measures medication and sends patient reminders have emerged as prize-winners in a Healthcare …
Orphan drug for Astellas
May 29, 2013Sales and Marketing Astellas, Isavuconazole, Orphan
The FDA has granted orphan designation to one of Astellas’ Phase III drugs designed to treat potentially life-threatening fungal infections …
FDA experts recommend Merck sleep pill
May 24, 2013Research and Development, Sales and Marketing FDA, Merck, insomnia, suvorexant
Merck received welcome news this week from the FDA after one of the US regulator’s expert groups voted to approve …
Janssen outlines pipeline ambitions
May 24, 2013Research and Development, Sales and Marketing Janssen, Johnson and Johnson, pipeline
Janssen has outlined plans to submit ‘more than ten’ new product filings worldwide in the next four years, along with …
Hurel appoints Schering-Plough executive to its Board
May 24, 2013Manufacturing and Production, Research and Development, Sales and Marketing Hurel, Merck, Schering-Plough
Pre-clinical products firm Hurel has appointed Dr James MacDonald to the company’s Board of directors. MacDonald is the former executive …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
